Why SMM's Profit Collapsed in 2025
Sociedade Moçambicana de Medicamentos (SMM), Mozambique’s state-owned pharmaceutical company, reported net profit of just €137,000 for 2025, down 98.5% from €9.1 million in 2024. The group result is starker: after a €8.6 million profit in 2024, the consolidated SMM group closed 2025 with a loss of around €1 million.
That earlier performance was not driven by day-to-day business. In 2024 SMM booked roughly €9 million in exceptional gains from the revaluation of its 49% stake in Indústria Farmacêutica de Moçambique (Infarma), after a capital increase carried out under the shareholders’ agreement. The operation did not change SMM’s ownership share, but it flattered the 2024 accounts.
Without that one-off, the operating weakness is visible in the sales line: revenue fell from €1.7 million in 2024 to €872,000 in 2025, a decline of almost 48%. Ethyl alcohol accounted for about €827,000 of that total, leaving the company heavily dependent on a single product.
What the Numbers Reveal About SMM's Operating Base
The Infarma Gain Was Accounting, Not Operating Strength
The gap between the 2024 and 2025 results is largely a base effect. SMM’s 2024 profit was inflated by a non-recurring gain tied to Infarma’s capital increase; because the transaction preserved the existing 49% shareholding, it did not create new cash-generating capacity at SMM. The 2025 figures therefore give a more realistic view of what the trading business itself produces.
Sales Depend Almost Entirely on Ethyl Alcohol
The revenue composition is the clearest warning sign. With ethyl alcohol generating roughly €827,000 of the €872,000 total, a single product represented close to 95% of sales in 2025. That leaves little evidence of a broad pharmaceutical distribution or manufacturing base, and it makes revenue sensitive to changes in demand or pricing for one commodity-type item.
A Strategic State Asset With a Thin Operating Core
For a state-owned company placed in a sector linked to Mozambique’s health sovereignty, the figures matter beyond accounting. The sharp drop in sales and the concentration of revenue in one product suggest the company currently has limited commercial scale. The retained 49% Infarma stake still gives SMM a position in local pharmaceutical manufacturing, but the 2025 result shows that ownership value alone is not replacing the need for stronger operating income.
Policy and Management Priorities After the 2025 Accounts
For Mozambican policymakers and SMM management, the 2025 accounts point to three specific priorities:
- Rebuild the trading base after the one-off. With core sales down from €1.7 million to €872,000, future budgets should not assume another exceptional gain; the group already swung to a €1 million consolidated loss.
- Reduce dependence on ethyl alcohol. That product supplied about €827,000 of €872,000 in revenue, meaning the company’s commercial result is currently tied to a single line rather than a diversified pharmaceutical portfolio.
- Translate the Infarma stake into operational value. The 49% holding was preserved through the capital increase, but it has not offset the contraction in SMM’s own sales; strengthening procurement, distribution or local production capacity will be the test for the next accounts.
Risk & Opportunity Assessment
| Commercial Risk | High | SMM's revenue fell about 48% to €872,000 in 2025, and ethyl alcohol accounted for roughly €827,000 of that total, leaving the core business highly exposed to a single product. |
| Competitive Risk | Medium | The near-total dependence on ethyl alcohol suggests a narrow commercial position, although no direct competitors are identified in the source. |
| Regulatory Risk | Low | The story identifies no new regulatory action; the main exposure is future state-owner or government intervention prompted by the poor operating result. |
| Reputation Risk | Medium | A 98.5% profit collapse at a state-owned company and a consolidated loss of about €1 million could raise questions about SMM's management and strategic direction. |
| Technology Disruption | Low | No technological change or disruption is described in the article; the issue is operating scale and revenue concentration. |
| Commercial Opportunity | Medium | SMM retains a 49% stake in Infarma and remains positioned in Mozambique's strategic local pharmaceutical production sector, but it has not yet converted that position into strong operating income. |
Comments 0